Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Febit Achieves Sales Goals

Published: Thursday, March 16, 2006
Last Updated: Monday, March 27, 2006
Bookmark and Share
Febit successfully markets the GENIOM bioanalysis device.

Febit biotech gmbh has announced that it has successfully concluded the business year, meeting its sales goals for 2005.

Sales of GENIOM™, a biochip-driven nucleic acid analysis system, were on budget already in the year of Febit's re-establishment.

This development is based on the fundamental restructuring and re-establishment of Febit biotech gmbh in spring 2005 when the company moved into new quarters in the Heidelberg Technologiepark.

Since its reorganization, Febit is supported by Dietmar and Oliver Hopp, two experienced biotech investors interested in a favourable long-term development of the company.

Integrating its structural and financial basis, Febit's re-establishment was supported by Prof. Christof Hettich, an experienced consultant from the Rittershaus firm of Mannheim.

In October 2005 the management team around Cord F. Stahler, CEO of Febit biotech gmbh was expanded, a supervisory board was established and the headcount was gradually increased.

The team consisting of management, staff and supervisory board boasts know-how and skills in all relevant areas. 

Febit has become a valuable cooperation partner in the biotech field, which is illustrated by a number of licence agreements signed in late 2005.

From Oxford Gene Technology, Febit acquired a license for the southern array technique, a method of major impact in gene research, thus enhancing its position with respect to intellectual property on the global market.

In a license agreement with the German Cancer Reseach Center (DKFZ), Febit acquired the rights to an alternative high-efficacy DNA synthesis method for use in its GENIOM® platform.       

Dr. Jorg Hoheisel at the DKFZ strongly supports the GENIOM® platform, said, "This DNA analysis device offers tremendous flexibility and has an extraordinary potential. It is invaluable for many aspects of our work at the DKFZ."   

The product website went online recently, complementing the corporate website and broadening Febit´s internet information resources for customers, investors and the public.

In February 2005, the Febit facilities were substantially enlarged and the headcount will reach 50 at the end of 2006 in order to realize the expansion plans and to ensure reliable product quality and availability. 

Cord F. Stahler, Chief Executive Officer of Febit biotech gmbh is confident to generate substantial growth within 2006, "The changes we made in 2005 and our network allow us to rapidly expand our position on the international market."

"The global market of DNA analysis devices will keep growing substantially in the next years. Febit will participate in this growth due to significant product advantages and the market-readiness of GENIOM®."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Decoding the RNA Operating System of the Cell with Up-to-date miRNA Profiling Service
According to febit, its new microRNA profiling services can make researchers stay ahead in microRNA research.
Tuesday, September 11, 2007
Geniom Technology Applied to Targeted Next-Generation Sequencing
By enabling selective targeting, the Geniom® Biochip will allow researchers to sequence individual and well defined parts of genomes
Tuesday, July 24, 2007
Febit Establishes US Company
Febit launches the GENIOM biochip system in the US.
Tuesday, August 15, 2006
Scientific News
Paving the way to Better Ovarian Cancer Diagnosis
Aïcha BenTaieb will present her invention for automated identification of ovarian cancer’s many subtypes at an international conference this fall.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Futuristic Brain Probe Allows for Wireless Control of Neurons
NIH-funded scientists developed an ultra-thin, minimally invasive device for controlling brain cells with drugs and light.
Microfluidic Device Mixes And Matches DNA For Synthetic Biology
Researchers have developed a microfluidic device that quickly builds packages of DNA and delivers them into bacteria or yeast for further testing.
Artificial Pancreas Controls Diabetes
Scientists are reporting the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar, or glucose, level and can automatically release insulin as needed.
Major Step for Implantable Drug-Delivery Device
MIT spinout signs deal to commercialize microchips that release therapeutics inside the body.
Smart Insulin Patch Could Replace Painful Injections for Diabetes
A joint effort between diabetes doctors and biomedical engineers could revolutionize how people with diabetes keep their blood sugar levels in check.
The Secrets of Secretion
Researchers have hacked nature's blueprints to create a new technology that could have broad-reaching impact on drug delivery systems and self-healing and anti-fouling materials.
New Tool on Horizon for Surgeons Treating Cancer Patients
Surgeons could know while their patients are still on the operating table if a tissue is cancerous, according to researchers.
Heartbeat on a Chip Could Improve Pharmaceutical Tests
A gravity-powered chip that can mimic a human heartbeat outside the body could advance pharmaceutical testing and open new possibilities in cell culture because it can mimic fundamental physical rhythms.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!